{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T06:40:43Z","timestamp":1793083243692,"version":"4.5.0"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T00:00:00Z","timestamp":1720396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T00:00:00Z","timestamp":1720396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005626","name":"Universit\u00e4t Regensburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005626","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Psychiatry Clin Neurosci"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Recently, the gamma-aminobutyric acid (GABA) system has come into focus for the treatment of anxiety, postpartum depression, and major depressive disorder. Endogenous 3\u03b1-reduced steroids such as allopregnanolone are potent positive allosteric modulators of GABA<jats:sub>A<\/jats:sub> receptors and have been known for decades. Current industry developments and first approvals by the U.S. food and drug administration (FDA) for the treatment of postpartum depression with exogenous analogues of these steroids represent a major step forward in the field. 3\u03b1-reduced steroids target both synaptic and extrasynaptic GABA<jats:sub>A<\/jats:sub> receptors, unlike benzodiazepines, which bind to synaptic receptors. The first FDA-approved 3\u03b1-reduced steroid for postpartum depression is brexanolone, an intravenous formulation of allopregnanolone. It has been shown to provide rapid relief of depressive symptoms. An orally available 3\u03b1-reduced steroid is zuranolone, which also received FDA approval in 2023 for the treatment of postpartum depression. Although a number of studies have been conducted, the efficacy data were not sufficient to achieve approval of zuranolone in major depressive disorder by the FDA in 2023. The most prominent side effects of these 3\u03b1-reduced steroids are somnolence, dizziness and headache. In addition to the issue of efficacy, it should be noted that current data limit the use of these compounds to two weeks. An alternative to exogenous 3\u03b1-reduced steroids may be the use of substances that induce endogenous neurosteroidogenesis, such as the translocator protein 18\u00a0kDa (TSPO) ligand etifoxine. TSPO has been extensively studied for its role in steroidogenesis, in addition to other functions such as anti-inflammatory and neuroregenerative properties. Currently, etifoxine is the only clinically available TSPO ligand in France for the treatment of anxiety disorders. Studies are underway to evaluate its antidepressant potential. Hopefully, neurosteroid research will lead to the development of fast-acting antidepressants.<\/jats:p>","DOI":"10.1007\/s00406-024-01843-7","type":"journal-article","created":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T09:02:00Z","timestamp":1720429320000},"page":"1581-1591","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Neurosteroids and translocator protein 18\u00a0kDa (TSPO) ligands as novel treatment options in depression"],"prefix":"10.1007","volume":"275","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2177-3884","authenticated-orcid":false,"given":"Marco","family":"Riebel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa-Marie","family":"Brunner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Nothdurfter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Wein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Schwarzbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Liere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schumacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Rupprecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,8]]},"reference":[{"key":"1843_CR1","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1016\/S0140-6736(18)31948-2","volume":"392","author":"GS Malhi","year":"2018","unstructured":"Malhi GS, Mann JJ (2018) Depression. The Lancet 392:2299\u20132312. https:\/\/doi.org\/10.1016\/S0140-6736(18)31948-2","journal-title":"The Lancet"},{"key":"1843_CR2","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1093\/ijnp\/pyz062","volume":"23","author":"Q Cheng","year":"2020","unstructured":"Cheng Q, Huang J, Xu L, Li Y, Li H, Shen Y, Zheng Q, Li L (2020) Analysis of Time-Course, Dose-Effect, and influencing factors of antidepressants in the treatment of Acute adult patients with Major Depression. Int J Neuropsychopharmacol 23:76\u201387. https:\/\/doi.org\/10.1093\/ijnp\/pyz062","journal-title":"Int J Neuropsychopharmacol"},{"key":"1843_CR3","doi-asserted-by":"publisher","first-page":"4","DOI":"10.12788\/acp.0048","volume":"33","author":"M Kritzer","year":"2021","unstructured":"Kritzer M (2021) Ketamine for treatment of mood disorders and suicidality: a narrative review of recent progress. Ann Clin Psychiatry 33:4. https:\/\/doi.org\/10.12788\/acp.0048","journal-title":"Ann Clin Psychiatry"},{"key":"1843_CR4","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.3390\/jcm10091809","volume":"10","author":"O S\u00e1iz-V\u00e1zquez","year":"2021","unstructured":"S\u00e1iz-V\u00e1zquez O, Gracia-Garc\u00eda P, Ubillos-Landa S, Puente-Mart\u00ednez A, Casado-Yusta S, Olaya B, Santab\u00e1rbara J (2021) Depression as a risk factor for Alzheimer\u2019s Disease: a systematic review of longitudinal Meta-analyses. J Clin Med 10:1809. https:\/\/doi.org\/10.3390\/jcm10091809","journal-title":"J Clin Med"},{"key":"1843_CR5","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1038\/s41380-022-01561-3","volume":"27","author":"R Rupprecht","year":"2022","unstructured":"Rupprecht R, Wetzel CH, Dorostkar M, Herms J, Albert NL, Schwarzbach J, Schumacher M, Neumann ID (2022) Translocator protein (18\u00a0kDa) TSPO: a new diagnostic or therapeutic target for stress-related disorders? Mol Psychiatry 27:2918\u20132926. https:\/\/doi.org\/10.1038\/s41380-022-01561-3","journal-title":"Mol Psychiatry"},{"key":"1843_CR6","doi-asserted-by":"publisher","first-page":"594","DOI":"10.3390\/neurolint13040059","volume":"13","author":"AN Edinoff","year":"2021","unstructured":"Edinoff AN, Nix CA, Hollier J, Sagrera CE, Delacroix BM, Abubakar T, Cornett EM, Kaye AM, Kaye AD (2021) Benzodiazepines: uses, dangers, and clinical considerations. Neurol Int 13:594\u2013607. https:\/\/doi.org\/10.3390\/neurolint13040059","journal-title":"Neurol Int"},{"key":"1843_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40263-015-0305-4","volume":"30","author":"A Pariente","year":"2016","unstructured":"Pariente A, De Gage SB, Moore N, B\u00e9gaud B (2016) The benzodiazepine\u2013dementia disorders Link: current state of knowledge. CNS Drugs 30:1\u20137. https:\/\/doi.org\/10.1007\/s40263-015-0305-4","journal-title":"CNS Drugs"},{"key":"1843_CR8","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/S0887-6177(03)00096-9","volume":"19","author":"M Barker","year":"2004","unstructured":"Barker M (2004) Persistence of cognitive effects after withdrawal from long-term benzodiazepine use: a meta-analysis. Arch Clin Neuropsychol 19:437\u2013454. https:\/\/doi.org\/10.1016\/S0887-6177(03)00096-9","journal-title":"Arch Clin Neuropsychol"},{"key":"1843_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001026","author":"TA Furukawa","year":"2001","unstructured":"Furukawa TA, Streiner D, Young LT, Kinoshita Y (2001) Antidepressants plus benzodiazepines for major depression. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD001026","journal-title":"Cochrane Database Syst Rev"},{"key":"1843_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001026.pub2","author":"Y Ogawa","year":"2019","unstructured":"Ogawa Y, Takeshima N, Hayasaka Y, Tajika A, Watanabe N, Streiner D, Furukawa TA (2019) Antidepressants plus benzodiazepines for adults with major depression. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD001026.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"1843_CR11","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1007\/s00406-022-01532-3","volume":"273","author":"R Rupprecht","year":"2022","unstructured":"Rupprecht R, Pradhan AK, Kufner M, Brunner LM, Nothdurfter C, Wein S, Schwarzbach J, Puig X, Rupprecht C, Rammes G (2022) Neurosteroids and translocator protein 18\u00a0kDa (TSPO) in depression: implications for synaptic plasticity, cognition, and treatment options. Eur Arch Psychiatry Clin Neurosci 273:1477\u20131487. https:\/\/doi.org\/10.1007\/s00406-022-01532-3","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"1843_CR12","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0166-2236(99)01399-5","volume":"22","author":"R Rupprecht","year":"1999","unstructured":"Rupprecht R, Holsboer F (1999) Neuroactive steroids: mechanisms of action and neuropsychopharmacological perspectives. Trends Neurosci 22:410\u2013416. https:\/\/doi.org\/10.1016\/S0166-2236(99)01399-5","journal-title":"Trends Neurosci"},{"key":"1843_CR13","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.tips.2006.06.005","volume":"27","author":"V Papadopoulos","year":"2006","unstructured":"Papadopoulos V, Baraldi M, Guilarte TR, Knudsen TB, Lacap\u00e8re J-J, Lindemann P, Norenberg MD, Nutt D, Weizman A, Zhang M-R, Gavish M (2006) Translocator protein (18\u00a0kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol Sci 27:402\u2013409. https:\/\/doi.org\/10.1016\/j.tips.2006.06.005","journal-title":"Trends Pharmacol Sci"},{"key":"1843_CR14","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1038\/nrd3295","volume":"9","author":"R Rupprecht","year":"2010","unstructured":"Rupprecht R, Papadopoulos V, Rammes G, Baghai TC, Fan J, Akula N, Groyer G, Adams D, Schumacher M (2010) Translocator protein (18\u00a0kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders. Nat Rev Drug Discov 9:971\u2013988. https:\/\/doi.org\/10.1038\/nrd3295","journal-title":"Nat Rev Drug Discov"},{"key":"1843_CR15","doi-asserted-by":"publisher","first-page":"e3000157","DOI":"10.1371\/journal.pbio.3000157","volume":"17","author":"Z-W Chen","year":"2019","unstructured":"Chen Z-W, Bracamontes JR, Budelier MM, Germann AL, Shin DJ, Kathiresan K, Qian M-X, Manion B, Cheng WWL, Reichert DE, Akk G, Covey DF, Evers AS (2019) Multiple functional neurosteroid binding sites on GABAA receptors. PLOS Biol 17:e3000157. https:\/\/doi.org\/10.1371\/journal.pbio.3000157","journal-title":"PLOS Biol"},{"key":"1843_CR16","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1038\/44579","volume":"401","author":"U Rudolph","year":"1999","unstructured":"Rudolph U, Crestani F, Benke D, Br\u00fcnig I, Benson JA, Fritschy J-M, Martin JR, Bluethmann H, M\u00f6hler H (1999) Benzodiazepine actions mediated by specific \u03b3-aminobutyric acidA receptor subtypes. Nature 401:796\u2013800. https:\/\/doi.org\/10.1038\/44579","journal-title":"Nature"},{"key":"1843_CR17","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.tips.2023.06.009","volume":"44","author":"B Luscher","year":"2023","unstructured":"Luscher B, Maguire JL, Rudolph U, Sibille E (2023) GABAA receptors as targets for treating affective and cognitive symptoms of depression. Trends Pharmacol Sci 44:586\u2013600. https:\/\/doi.org\/10.1016\/j.tips.2023.06.009","journal-title":"Trends Pharmacol Sci"},{"key":"1843_CR18","doi-asserted-by":"publisher","first-page":"3226","DOI":"10.1111\/bph.13843","volume":"174","author":"A Locci","year":"2017","unstructured":"Locci A, Pinna G (2017) Neurosteroid biosynthesis down-regulation and changes in GABA A receptor subunit composition: a biomarker axis in stress\u2010induced cognitive and emotional impairment. Br J Pharmacol 174:3226\u20133241. https:\/\/doi.org\/10.1111\/bph.13843","journal-title":"Br J Pharmacol"},{"key":"1843_CR19","doi-asserted-by":"publisher","first-page":"100215","DOI":"10.1016\/j.ynstr.2020.100215","volume":"12","author":"SM Paul","year":"2020","unstructured":"Paul SM, Pinna G, Guidotti A (2020) Allopregnanolone: from molecular pathophysiology to therapeutics. A historical perspective. Neurobiol Stress 12:100215. https:\/\/doi.org\/10.1016\/j.ynstr.2020.100215","journal-title":"Neurobiol Stress"},{"key":"1843_CR20","doi-asserted-by":"publisher","first-page":"108333","DOI":"10.1016\/j.neuropharm.2020.108333","volume":"181","author":"AL Althaus","year":"2020","unstructured":"Althaus AL, Ackley MA, Belfort GM, Gee SM, Dai J, Nguyen DP, Kazdoba TM, Modgil A, Davies PA, Moss SJ, Salituro FG, Hoffmann E, Hammond RS, Robichaud AJ, Quirk MC, Doherty JJ (2020) Preclinical characterization of zuranolone (SAGE-217), a selective neuroactive steroid GABAA receptor positive allosteric modulator. Neuropharmacology 181:108333. https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108333","journal-title":"Neuropharmacology"},{"key":"1843_CR21","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.neubiorev.2012.10.005","volume":"37","author":"CF Zorumski","year":"2013","unstructured":"Zorumski CF, Paul SM, Izumi Y, Covey DF, Mennerick S (2013) Neurosteroids, stress and depression: potential therapeutic opportunities. Neurosci Biobehav Rev 37:109\u2013122. https:\/\/doi.org\/10.1016\/j.neubiorev.2012.10.005","journal-title":"Neurosci Biobehav Rev"},{"key":"1843_CR22","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1176\/ajp.155.7.910","volume":"155","author":"E Romeo","year":"1998","unstructured":"Romeo E, Str\u00f6hle A, Spalletta G, Michele FD, Hermann B, Holsboer F, Pasini A, Rupprecht R (1998) Effects of antidepressant treatment on neuroactive steroids in Major Depression. Am J Psychiatry 155:910\u2013913. https:\/\/doi.org\/10.1176\/ajp.155.7.910","journal-title":"Am J Psychiatry"},{"key":"1843_CR23","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1073\/pnas.95.6.3239","volume":"95","author":"V Uzunova","year":"1998","unstructured":"Uzunova V, Sheline Y, Davis JM, Rasmusson A, Uzunov DP, Costa E, Guidotti A (1998) Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc Natl Acad Sci 95:3239\u20133244. https:\/\/doi.org\/10.1073\/pnas.95.6.3239","journal-title":"Proc Natl Acad Sci"},{"key":"1843_CR24","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1001\/archpsyc.60.2.161","volume":"60","author":"A Str\u00f6hle","year":"2003","unstructured":"Str\u00f6hle A, Romeo E, Di Michele F, Pasini A, Hermann B, Gajewsky G, Holsboer F, Rupprecht R (2003) Induced panic attacks Shift \u03b3-Aminobutyric acid type a receptor Modulatory Neuroactive Steroid Composition in patients with panic disorder: preliminary results. Arch Gen Psychiatry 60:161. https:\/\/doi.org\/10.1001\/archpsyc.60.2.161","journal-title":"Arch Gen Psychiatry"},{"key":"1843_CR25","doi-asserted-by":"publisher","first-page":"13512","DOI":"10.1073\/pnas.96.23.13512","volume":"96","author":"LD Griffin","year":"1999","unstructured":"Griffin LD, Mellon SH (1999) Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes. Proc Natl Acad Sci 96:13512\u201313517. https:\/\/doi.org\/10.1073\/pnas.96.23.13512","journal-title":"Proc Natl Acad Sci"},{"key":"1843_CR26","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/sj.mp.4001782","volume":"11","author":"C Sch\u00fcle","year":"2006","unstructured":"Sch\u00fcle C, Romeo E, Uzunov DP, Eser D, Di Michele F, Baghai TC, Pasini A, Schwarz M, Kempter H, Rupprecht R (2006) Influence of mirtazapine on plasma concentrations of neuroactive steroids in major depression and on 3\u03b1-hydroxysteroid dehydrogenase activity. Mol Psychiatry 11:261\u2013272. https:\/\/doi.org\/10.1038\/sj.mp.4001782","journal-title":"Mol Psychiatry"},{"key":"1843_CR27","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/sj.npp.1300084","volume":"28","author":"C Sch\u00fcle","year":"2003","unstructured":"Sch\u00fcle C, di Michele F, Baghai T, Romeo E, Bernardi G, Zwanzger P, Padberg F, Pasini A, Rupprecht R (2003) Influence of sleep deprivation major depression on neuroactive steroids in major depression. Neuropsychopharmacology 28:577\u2013581","journal-title":"Neuropsychopharmacology"},{"key":"1843_CR28","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/S0893-133X(02)00355-X","volume":"27","author":"F Padberg","year":"2002","unstructured":"Padberg F (2002) Plasma concentrations of neuroactive steroids before and after Repetitive Transcranial Magnetic Stimulation (rTMS) in Major Depression. Neuropsychopharmacology 27:874\u2013878. https:\/\/doi.org\/10.1016\/S0893-133X(02)00355-X","journal-title":"Neuropsychopharmacology"},{"key":"1843_CR29","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1038\/sj.npp.1300684","volume":"30","author":"TC Baghai","year":"2005","unstructured":"Baghai TC, Di Michele F, Sch\u00fcle C, Eser D, Zwanzger P, Pasini A, Romeo E, Rupprecht R (2005) Plasma concentrations of neuroactive steroids before and after Electroconvulsive Therapy in Major Depression. Neuropsychopharmacology 30:1181\u20131186. https:\/\/doi.org\/10.1038\/sj.npp.1300684","journal-title":"Neuropsychopharmacology"},{"key":"1843_CR30","doi-asserted-by":"publisher","first-page":"104827","DOI":"10.1016\/j.psyneuen.2020.104827","volume":"121","author":"KM Deligiannidis","year":"2020","unstructured":"Deligiannidis KM, Kroll-Desrosiers AR, Tan Y, Dubuke ML, Shaffer SA (2020) Longitudinal proneuroactive and neuroactive steroid profiles in medication-free women with, without and at-risk for perinatal depression: a liquid chromatography-tandem mass spectrometry analysis. Psychoneuroendocrinology 121:104827. https:\/\/doi.org\/10.1016\/j.psyneuen.2020.104827","journal-title":"Psychoneuroendocrinology"},{"key":"1843_CR31","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1007\/s00213-016-4258-1","volume":"233","author":"E Timby","year":"2016","unstructured":"Timby E, B\u00e4ckstr\u00f6m T, Nyberg S, Stenlund H, Wihlb\u00e4ck A-CN, Bixo M (2016) Women with premenstrual dysphoric disorder have altered sensitivity to allopregnanolone over the menstrual cycle compared to controls\u2014a pilot study. Psychopharmacology 233:2109\u20132117. https:\/\/doi.org\/10.1007\/s00213-016-4258-1","journal-title":"Psychopharmacology"},{"key":"1843_CR32","doi-asserted-by":"publisher","first-page":"100198","DOI":"10.1016\/j.ynstr.2019.100198","volume":"11","author":"N Walton","year":"2019","unstructured":"Walton N, Maguire J (2019) Allopregnanolone-based treatments for postpartum depression: Why\/how do they work? Neurobiol Stress 11:100198. https:\/\/doi.org\/10.1016\/j.ynstr.2019.100198","journal-title":"Neurobiol Stress"},{"key":"1843_CR33","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1177\/1060028019873320","volume":"54","author":"JG Powell","year":"2020","unstructured":"Powell JG, Garland S, Preston K, Piszczatoski C (2020) Brexanolone (Zulresso): finally, an FDA-Approved treatment for Postpartum Depression. Ann Pharmacother 54:157\u2013163. https:\/\/doi.org\/10.1177\/1060028019873320","journal-title":"Ann Pharmacother"},{"key":"1843_CR34","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/S0140-6736(17)31264-3","volume":"390","author":"S Kanes","year":"2017","unstructured":"Kanes S, Colquhoun H, Gunduz-Bruce H, Raines S, Arnold R, Schacterle A, Doherty J, Epperson CN, Deligiannidis KM, Riesenberg R, Hoffmann E, Rubinow D, Jonas J, Paul S, Meltzer-Brody S (2017) Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial. Lancet 390:480\u2013489. https:\/\/doi.org\/10.1016\/S0140-6736(17)31264-3","journal-title":"Lancet"},{"key":"1843_CR35","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/S0140-6736(18)31551-4","volume":"392","author":"S Meltzer-Brody","year":"2018","unstructured":"Meltzer-Brody S, Colquhoun H, Riesenberg R, Epperson CN, Deligiannidis KM, Rubinow DR, Li H, Sankoh AJ, Clemson C, Schacterle A, Jonas J, Kanes S (2018) Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet 392:1058\u20131070. https:\/\/doi.org\/10.1016\/S0140-6736(18)31551-4","journal-title":"Lancet"},{"key":"1843_CR36","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.jad.2022.09.143","volume":"320","author":"CN Epperson","year":"2023","unstructured":"Epperson CN, Rubinow DR, Meltzer-Brody S, Deligiannidis KM, Riesenberg R, Krystal AD, Bankole K, Huang M-Y, Li H, Brown C, Kanes SJ, Lasser R (2023) Effect of brexanolone on depressive symptoms, anxiety, and insomnia in women with postpartum depression: pooled analyses from 3 double-blind, randomized, placebo-controlled clinical trials in the HUMMINGBIRD clinical program. J Affect Disord 320:353\u2013359. https:\/\/doi.org\/10.1016\/j.jad.2022.09.143","journal-title":"J Affect Disord"},{"key":"1843_CR37","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s40801-023-00372-4","volume":"10","author":"S Garafola","year":"2023","unstructured":"Garafola S, Shiferaw E, Dev V (2023) Safety of Brexanolone in adults with Postpartum Depression: Postmarketing Surveillance Data. Drugs - Real World Outcomes 10:351\u2013356. https:\/\/doi.org\/10.1007\/s40801-023-00372-4","journal-title":"Drugs - Real World Outcomes"},{"key":"1843_CR38","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1007\/s40265-023-01953-x","volume":"83","author":"Y-A Heo","year":"2023","unstructured":"Heo Y-A (2023) Zuranolone: first approval. Drugs 83:1559\u20131567. https:\/\/doi.org\/10.1007\/s40265-023-01953-x","journal-title":"Drugs"},{"key":"1843_CR39","doi-asserted-by":"publisher","first-page":"0","DOI":"10.1177\/10600280231204953","volume":"0","author":"KN Barnes","year":"2023","unstructured":"Barnes KN, Vogl CM, Nelson LA (2023) Zuranolone: the first FDA-Approved oral treatment option for Postpartum Depression. Ann Pharmacother 0:0. https:\/\/doi.org\/10.1177\/10600280231204953","journal-title":"Ann Pharmacother"},{"key":"1843_CR40","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1001\/jamapsychiatry.2021.1559","volume":"78","author":"KM Deligiannidis","year":"2021","unstructured":"Deligiannidis KM, Meltzer-Brody S, Gunduz-Bruce H, Doherty J, Jonas J, Li S, Sankoh AJ, Silber C, Campbell AD, Werneburg B, Kanes SJ, Lasser R (2021) Effect of Zuranolone vs Placebo in Postpartum Depression: a Randomized Clinical Trial. JAMA Psychiatry 78:951. https:\/\/doi.org\/10.1001\/jamapsychiatry.2021.1559","journal-title":"JAMA Psychiatry"},{"key":"1843_CR41","doi-asserted-by":"publisher","first-page":"e2806","DOI":"10.1002\/hup.2806","volume":"37","author":"A Bullock","year":"2022","unstructured":"Bullock A, Gunduz-Bruce H, Zammit GK, Qin M, Li H, Sankoh AJ, Silber C, Kanes SJ, Jonas J, Doherty J (2022) A phase 1 double\u2010blind, placebo\u2010controlled study of zuranolone (SAGE\u2010217) in a phase advance model of insomnia in healthy adults. Hum Psychopharmacol Clin Exp 37:e2806. https:\/\/doi.org\/10.1002\/hup.2806","journal-title":"Hum Psychopharmacol Clin Exp"},{"key":"1843_CR42","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1056\/NEJMoa1815981","volume":"381","author":"H Gunduz-Bruce","year":"2019","unstructured":"Gunduz-Bruce H, Silber C, Kaul I, Rothschild AJ, Riesenberg R, Sankoh AJ, Li H, Lasser R, Zorumski CF, Rubinow DR, Paul SM, Jonas J, Doherty JJ, Kanes SJ (2019) Trial of SAGE-217 in patients with major depressive disorder. N Engl J Med 381:903\u2013911. https:\/\/doi.org\/10.1056\/NEJMoa1815981","journal-title":"N Engl J Med"},{"key":"1843_CR43","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jad.2022.03.068","volume":"308","author":"E Suthoff","year":"2022","unstructured":"Suthoff E, Kosinski M, Arnaud A, Hodgkins P, Gunduz-Bruce H, Lasser R, Silber C, Sankoh AJ, Li H, Werneburg B, Jonas J, Doherty J, Kanes SJ, Bonthapally V (2022) Patient-reported health-related quality of life from a randomized, placebo-controlled phase 2 trial of zuranolone in adults with major depressive disorder. J Affect Disord 308:19\u201326. https:\/\/doi.org\/10.1016\/j.jad.2022.03.068","journal-title":"J Affect Disord"},{"key":"1843_CR44","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jad.2021.02.027","volume":"285","author":"A Arnaud","year":"2021","unstructured":"Arnaud A, Suthoff E, Stenson K, Werneburg B, Hodgkins P, Bonthapally V, Jonas J, Meyer K, O\u2019Day K (2021) Number needed to treat and Number needed to harm analysis of the zuranolone phase 2 clinical trial results in major depressive disorder. J Affect Disord 285:112\u2013119. https:\/\/doi.org\/10.1016\/j.jad.2021.02.027","journal-title":"J Affect Disord"},{"key":"1843_CR45","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1176\/appi.ajp.20220459","volume":"180","author":"AH Clayton","year":"2023","unstructured":"Clayton AH, Lasser R, Parikh SV, Iosifescu DV, Jung J, Kotecha M, Forrestal F, Jonas J, Kanes SJ, Doherty J (2023) Zuranolone for the treatment of adults with major depressive disorder: a Randomized, Placebo-Controlled phase 3 trial. Am J Psychiatry 180:676\u2013684. https:\/\/doi.org\/10.1176\/appi.ajp.20220459","journal-title":"Am J Psychiatry"},{"key":"1843_CR46","doi-asserted-by":"publisher","first-page":"22m14445","DOI":"10.4088\/JCP.22m14445","volume":"84","author":"AH Clayton","year":"2023","unstructured":"Clayton AH, Lasser R, Nandy I, Sankoh AJ, Jonas J, Kanes SJ (2023) Zuranolone in major depressive disorder: results from MOUNTAIN\u2014A phase 3, Multicenter, Double-Blind, randomized, Placebo\u2010Controlled Trial. J Clin Psychiatry 84:22m14445. https:\/\/doi.org\/10.4088\/JCP.22m14445","journal-title":"J Clin Psychiatry"},{"key":"1843_CR47","doi-asserted-by":"publisher","first-page":"23m14845","DOI":"10.4088\/JCP.23m14845","volume":"85","author":"AJ Cutler","year":"2023","unstructured":"Cutler AJ, Mattingly GW, Kornstein SG, Aaronson ST, Lasser R, Zhang H, Rana N, Brown C, Levin S, Miller C, Kotecha M, Forrestal F, Doherty J (2023) Long-term safety and efficacy of initial and repeat treatment courses with zuranolone in adult patients with major depressive disorder: interim results from the Open-Label, phase 3 SHORELINE Study. J Clin Psychiatry 85:23m14845. https:\/\/doi.org\/10.4088\/JCP.23m14845","journal-title":"J Clin Psychiatry"},{"key":"1843_CR48","doi-asserted-by":"publisher","first-page":"102308","DOI":"10.1016\/j.eclinm.2023.102308","volume":"66","author":"Y-W Lin","year":"2023","unstructured":"Lin Y-W, Tu Y-K, Hung K-C, Liang C-S, Tseng P-T, Lin P-Y, Chia-Cheng Lai E, Hsu C-W (2023) Efficacy and safety of zuranolone in major depressive disorder: a meta-analysis of factor effect and dose-response analyses. eClinicalMedicine 66:102308. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102308","journal-title":"eClinicalMedicine"},{"key":"1843_CR49","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1001\/jama.2023.26103","volume":"331","author":"V Prasad","year":"2024","unstructured":"Prasad V, Allely D (2024) Concerns that may limit the utility of Zuranolone. JAMA 331:105. https:\/\/doi.org\/10.1001\/jama.2023.26103","journal-title":"JAMA"},{"key":"1843_CR50","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1080\/15622975.2021.1961503","volume":"23","author":"R Rupprecht","year":"2022","unstructured":"Rupprecht R, Rupprecht C, Di Benedetto B, Rammes G (2022) Neuroinflammation and psychiatric disorders: relevance of C1q, translocator protein (18\u00a0kDa) (TSPO), and neurosteroids. World J Biol Psychiatry 23:257\u2013263. https:\/\/doi.org\/10.1080\/15622975.2021.1961503","journal-title":"World J Biol Psychiatry"},{"key":"1843_CR51","doi-asserted-by":"publisher","first-page":"7261","DOI":"10.1073\/pnas.1502670112","volume":"112","author":"J Fan","year":"2015","unstructured":"Fan J, Campioli E, Midzak A, Culty M, Papadopoulos V (2015) Conditional steroidogenic cell-targeted deletion of TSPO unveils a crucial role in viability and hormone-dependent steroid formation. Proc Natl Acad Sci 112:7261\u20137266. https:\/\/doi.org\/10.1073\/pnas.1502670112","journal-title":"Proc Natl Acad Sci"},{"key":"1843_CR52","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1210\/me.2015-1033","volume":"29","author":"V Selvaraj","year":"2015","unstructured":"Selvaraj V, Stocco DM, Tu LN (2015) Minireview: Translocator Protein (TSPO) and steroidogenesis: a reappraisal. Mol Endocrinol 29:490\u2013501. https:\/\/doi.org\/10.1210\/me.2015-1033","journal-title":"Mol Endocrinol"},{"key":"1843_CR53","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.3390\/ijms24032474","volume":"24","author":"P Liere","year":"2023","unstructured":"Liere P, Liu G-J, Pianos A, Middleton RJ, Banati RB, Akwa Y (2023) The Comprehensive Steroidome in Complete TSPO\/PBR knockout mice under basal conditions. Int J Mol Sci 24:2474. https:\/\/doi.org\/10.3390\/ijms24032474","journal-title":"Int J Mol Sci"},{"key":"1843_CR54","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/s41593-022-01013-9","volume":"25","author":"Y Shi","year":"2022","unstructured":"Shi Y, Cui M, Ochs K, Brendel M, Str\u00fcbing FL, Briel N, Eckenweber F, Zou C, Banati RB, Liu G-J, Middleton RJ, Rupprecht R, Rudolph U, Zeilhofer HU, Rammes G, Herms J, Dorostkar MM (2022) Long-term diazepam treatment enhances microglial spine engulfment and impairs cognitive performance via the mitochondrial 18\u00a0kDa translocator protein (TSPO). Nat Neurosci 25:317\u2013329. https:\/\/doi.org\/10.1038\/s41593-022-01013-9","journal-title":"Nat Neurosci"},{"key":"1843_CR55","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/s41398-023-02630-z","volume":"13","author":"AK Pradhan","year":"2023","unstructured":"Pradhan AK, Neum\u00fcller T, Klug C, Fuchs S, Schlegel M, Ballmann M, Tartler KJ, Pianos A, Garcia MS, Liere P, Schumacher M, Kreuzer M, Rupprecht R, Rammes G (2023) Chronic administration of XBD173 ameliorates cognitive deficits and neuropathology via 18\u00a0kDa translocator protein (TSPO) in a mouse model of Alzheimer\u2019s disease. Transl Psychiatry 13:332. https:\/\/doi.org\/10.1038\/s41398-023-02630-z","journal-title":"Transl Psychiatry"},{"key":"1843_CR56","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1055\/s-0034-1398507","volume":"48","author":"L Wolf","year":"2015","unstructured":"Wolf L, Bauer A, Melchner D, Hallof-Buestrich H, Stoertebecker P, Haen E, Kreutz M, Sarubin N, Milenkovic V, Wetzel C, Rupprecht R, Nothdurfter C (2015) Enhancing Neurosteroid synthesis \u2013 relationship to the Pharmacology of Translocator protein (18\u00a0kDa) (TSPO) ligands and benzodiazepines. Pharmacopsychiatry 48:72\u201377. https:\/\/doi.org\/10.1055\/s-0034-1398507","journal-title":"Pharmacopsychiatry"},{"key":"1843_CR57","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1007\/s12035-020-02136-5","volume":"58","author":"AM Barron","year":"2021","unstructured":"Barron AM, Higuchi M, Hattori S, Kito S, Suhara T, Ji B (2021) Regulation of anxiety and depression by mitochondrial translocator protein-mediated steroidogenesis: the role of neurons. Mol Neurobiol 58:550\u2013563. https:\/\/doi.org\/10.1007\/s12035-020-02136-5","journal-title":"Mol Neurobiol"},{"key":"1843_CR58","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s00213-005-2247-x","volume":"181","author":"S Pini","year":"2005","unstructured":"Pini S, Martini C, Abelli M, Muti M, Gesi C, Montali M, Chelli B, Lucacchini A, Cassano GB (2005) Peripheral-type benzodiazepine receptor binding sites in platelets of patients with panic disorder associated to separation anxiety symptoms. Psychopharmacology 181:407\u2013411. https:\/\/doi.org\/10.1007\/s00213-005-2247-x","journal-title":"Psychopharmacology"},{"key":"1843_CR59","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1159\/000315440","volume":"62","author":"M Abelli","year":"2010","unstructured":"Abelli M, Chelli B, Costa B, Lari L, Cardini A, Gesi C, Muti M, Lucacchini A, Martini C, Cassano GB, Pini S (2010) Reductions in platelet 18-kDa Translocator Protein Density Are Associated with adult separation anxiety in patients with bipolar disorder. Neuropsychobiology 62:98\u2013103. https:\/\/doi.org\/10.1159\/000315440","journal-title":"Neuropsychobiology"},{"key":"1843_CR60","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1055\/s-0042-107795","volume":"49","author":"N Sarubin","year":"2016","unstructured":"Sarubin N, Baghai T, Lima-Ojeda J, Melchner D, Hallof-Buestrich H, Wolf L, Hilbert S, Milenkovic V, Wetzel C, Rupprecht R, Nothdurfter C (2016) Translocator Protein (TSPO) expression in platelets of depressed patients decreases during antidepressant therapy. Pharmacopsychiatry 49:204\u2013209. https:\/\/doi.org\/10.1055\/s-0042-107795","journal-title":"Pharmacopsychiatry"},{"key":"1843_CR61","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1001\/jamapsychiatry.2014.2427","volume":"72","author":"E Setiawan","year":"2015","unstructured":"Setiawan E, Wilson AA, Mizrahi R, Rusjan PM, Miler L, Rajkowska G, Suridjan I, Kennedy JL, Rekkas PV, Houle S, Meyer JH (2015) Role of Translocator Protein Density, a marker of Neuroinflammation, in the Brain during Major depressive episodes. JAMA Psychiatry 72:268. https:\/\/doi.org\/10.1001\/jamapsychiatry.2014.2427","journal-title":"JAMA Psychiatry"},{"key":"1843_CR62","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.jad.2018.08.021","volume":"241","author":"H Li","year":"2018","unstructured":"Li H, Sagar AP, K\u00e9ri S (2018) Microglial markers in the frontal cortex are related to cognitive dysfunctions in major depressive disorder. J Affect Disord 241:305\u2013310. https:\/\/doi.org\/10.1016\/j.jad.2018.08.021","journal-title":"J Affect Disord"},{"key":"1843_CR63","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1001\/jamapsychiatry.2017.1567","volume":"74","author":"S Attwells","year":"2017","unstructured":"Attwells S, Setiawan E, Wilson AA, Rusjan PM, Mizrahi R, Miler L, Xu C, Richter MA, Kahn A, Kish SJ, Houle S, Ravindran L, Meyer JH (2017) Inflammation in the neurocircuitry of obsessive-compulsive disorder. JAMA Psychiatry 74:833. https:\/\/doi.org\/10.1001\/jamapsychiatry.2017.1567","journal-title":"JAMA Psychiatry"},{"key":"1843_CR64","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.biopsych.2020.03.007","volume":"88","author":"S Attwells","year":"2020","unstructured":"Attwells S, Setiawan E, Rusjan PM, Xu C, Hutton C, Rafiei D, Varughese B, Kahn A, Kish SJ, Vasdev N, Houle S, Meyer JH (2020) Translocator protein distribution volume predicts reduction of symptoms during open-label trial of Celecoxib in Major Depressive Disorder. Biol Psychiatry 88:649\u2013656. https:\/\/doi.org\/10.1016\/j.biopsych.2020.03.007","journal-title":"Biol Psychiatry"},{"key":"1843_CR65","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1038\/s41467-020-15930-5","volume":"11","author":"S Bhatt","year":"2020","unstructured":"Bhatt S, Hilmer AT, Girgenti MJ, Rusowicz A, Kapinos M, Nabuls N (2020) PTSD is associated with neuroimmune suppression: evidence from PET imaging and postmortem transctriptional studies. Nat Commun 11:2360. https:\/\/doi.org\/10.1038\/s41467-020-15930-5","journal-title":"Nat Commun"},{"key":"1843_CR66","doi-asserted-by":"publisher","unstructured":"Tournier BB, Tsartsalis S, Ceyzeriat K, Garibotto V, Millet P (2020) In vivo TSPO signal and neuroinflammation in Alzheimer\u00b4s disease. Cells 9:1941. https:\/\/doi.org\/10.3390\/cells9091941","DOI":"10.3390\/cells9091941"},{"key":"1843_CR67","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1038\/s41380-020-0745-1","volume":"26","author":"T Notter","year":"2021","unstructured":"Notter T, Schalbetter SM, Clifton NE, Mattei D, Richetto J, Thomas K, Meyer U, Hall J (2021) Neuronal activity increases translocator protein (TSPO) levels. Mol Psychiatry 26:2025\u20132037. https:\/\/doi.org\/10.1038\/s41380-020-0745-1","journal-title":"Mol Psychiatry"},{"key":"1843_CR68","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.1016\/j.psyneuen.2013.07.007","volume":"38","author":"A Colasanti","year":"2013","unstructured":"Colasanti A, Owen DR, Grozeva D, Rabiner EA, Matthews PM, Craddock N, Young AH (2013) Bipolar disorder is associated with the rs6971 polymorphism in the gene encoding 18\u00a0kDa translocator protein (TSPO). Psychoneuroendocrinology 38:2826\u20132829. https:\/\/doi.org\/10.1016\/j.psyneuen.2013.07.007","journal-title":"Psychoneuroendocrinology"},{"key":"1843_CR69","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.psyneuen.2018.01.013","volume":"89","author":"AR Prossin","year":"2018","unstructured":"Prossin AR, Chandler M, Ryan KA, Saunders EF, Kamali M, Papadopoulos V, Z\u00f6llner S, Dantzer R, McInnis MG (2018) Functional TSPO polymorphism predicts variance in the diurnal cortisol rhythm in bipolar disorder. Psychoneuroendocrinology 89:194\u2013202. https:\/\/doi.org\/10.1016\/j.psyneuen.2018.01.013","journal-title":"Psychoneuroendocrinology"},{"key":"1843_CR70","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1126\/science.1175055","volume":"325","author":"R Rupprecht","year":"2009","unstructured":"Rupprecht R, Rammes G, Eser D, Baghai TC, Sch\u00fcle C, Nothdurfter C, Troxler T, Gentsch C, Kalkman HO, Chaperon F, Uzunov V, McAllister KH, Bertaina-Anglade V, La Rochelle CD, Tuerck D, Floesser A, Kiese B, Schumacher M, Landgraf R, Holsboer F, Kucher K (2009) Translocator Protein (18 kD) as target for Anxiolytics without Benzodiazepine-Like Side effects. Science 325:490\u2013493. https:\/\/doi.org\/10.1126\/science.1175055","journal-title":"Science"},{"key":"1843_CR71","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1177\/0269881119896304","volume":"34","author":"C Shang","year":"2020","unstructured":"Shang C, Yao RM, Guo Y, Ding ZC, Sun LJ, Ran YH (2020) Translocator protein-mediated fast-onset antidepressant-like and memory-enhancing effects in chronically stressed mice. J Psychopharmacol 34:441\u2013451. https:\/\/doi.org\/10.1177\/0269881119896304","journal-title":"J Psychopharmacol"},{"key":"1843_CR72","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1007\/s11064-020-03036-9","volume":"45","author":"P Ren","year":"2020","unstructured":"Ren P, Ma L, Wang J-Y, Guo H, Sun L, Gao M-L, Liu Y-Z, Ma Y-Q, Li Y-F, Guo W-Z (2020) Anxiolytic and anti-depressive like effects of Translocator protein (18\u00a0kDa) Ligand YL-IPA08 in a rat model of Postpartum Depression. Neurochem Res 45:1746\u20131757. https:\/\/doi.org\/10.1007\/s11064-020-03036-9","journal-title":"Neurochem Res"},{"key":"1843_CR73","doi-asserted-by":"publisher","first-page":"107835","DOI":"10.1016\/j.neuropharm.2019.107835","volume":"162","author":"K Nozaki","year":"2020","unstructured":"Nozaki K, Ito H, Ohgidani M, Yamawaki Y, Sahin EH, Kitajima T, Katsumata S, Yamawaki S, Kato TA, Aizawa H (2020) Antidepressant effect of the translocator protein antagonist ONO-2952 on mouse behaviors under chronic social defeat stress. Neuropharmacology 162:107835. https:\/\/doi.org\/10.1016\/j.neuropharm.2019.107835","journal-title":"Neuropharmacology"},{"key":"1843_CR74","doi-asserted-by":"publisher","first-page":"104250","DOI":"10.1016\/j.phrs.2019.04.034","volume":"145","author":"C Mattei","year":"2019","unstructured":"Mattei C, Taly A, Soualah Z, Saulais O, Henrion D, Gu\u00e9rineau NC, Verleye M, Legros C (2019) Involvement of the GABAA receptor \u03b1 subunit in the mode of action of etifoxine. Pharmacol Res 145:104250. https:\/\/doi.org\/10.1016\/j.phrs.2019.04.034","journal-title":"Pharmacol Res"},{"key":"1843_CR75","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/hup.757","volume":"21","author":"N Nguyen","year":"2006","unstructured":"Nguyen N, Fakra E, Pradel V, Jouve E, Alquier C, Guern ME (2006) Efficacy of etifoxine compared to lorazepam monotherapy in the treatment of patients with adjustment disorders with anxiety: a double-blind controlled study in general practice. Hum Psychopharmacol 21:139\u2013149. https:\/\/doi.org\/10.1002\/hup.757","journal-title":"Hum Psychopharmacol"},{"key":"1843_CR76","doi-asserted-by":"publisher","first-page":"3357","DOI":"10.1007\/s00213-020-05617-6","volume":"237","author":"B Vicente","year":"2020","unstructured":"Vicente B, Saldicia S, Hormazabal N, Bustos C, Rubi P (2020) Etifoxine is non-inferior than clonazepam for the reduction of anxiety disorders: a randomized, double blind, non-inferiority trial. Psychopharmacology 237:3357\u20133367. https:\/\/doi.org\/10.1007\/s00213-020-05617-6","journal-title":"Psychopharmacology"},{"key":"1843_CR77","doi-asserted-by":"publisher","first-page":"105100","DOI":"10.1016\/j.psyneuen.2020.105100","volume":"124","author":"LM Bahr","year":"2021","unstructured":"Bahr LM, Maurer F, Weigl J, Weber K, Melchner D, D\u00f6rfelt A (2021) Dissociation of endocrine responses to the Trier social stress test in virtual reality (VR-TSST) by the benzodiazepine alprazolam and the translocator protein 18\u00a0kDa (TSPO) ligand etifoxine. Psychoneuroendocrinology 124:105100. https:\/\/doi.org\/10.1016\/j.psyneuen.2020.105100","journal-title":"Psychoneuroendocrinology"},{"key":"1843_CR78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/S00213-022-06111-X\/FIGURES\/3","volume":"1","author":"LM Brunner","year":"2022","unstructured":"Brunner LM, Maurer F, Weber K, Weigl J, Milenkovic VM, Rupprecht R, Nothdurfter C, M\u00fchlberger A (2022) Differential effects of the translocator protein 18\u00a0kDa (TSPO) ligand etifoxine and the benzodiazepine alprazolam on startle response to predictable threat in a NPU-threat task after acute and short-term treatment. Psychopharmacology 1:1\u201312. https:\/\/doi.org\/10.1007\/S00213-022-06111-X\/FIGURES\/3","journal-title":"Psychopharmacology"},{"key":"1843_CR79","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1055\/a-2078-4823","volume":"56","author":"M Riebel","year":"2023","unstructured":"Riebel M, Von Pappenheim B, Kanig C, Nothdurfter C, Wetter TC, Rupprecht R, Schwarzbach J (2023) GABAergic effects of Etifoxine and Alprazolam assessed by double pulse TMS. Pharmacopsychiatry 56:154\u2013161. https:\/\/doi.org\/10.1055\/a-2078-4823","journal-title":"Pharmacopsychiatry"},{"key":"1843_CR80","doi-asserted-by":"publisher","first-page":"1188847","DOI":"10.3389\/fnins.2023.1188847","volume":"17","author":"A Manook","year":"2023","unstructured":"Manook A, Baghai TC, Riebel M, Nothdurfter C, Schwarzbach JV, Gessner A, Rupprecht R, Hiergeist A (2023) Short-term effects of etifoxine on human gut microbiome in healthy men. Front Neurosci 17:1188847. https:\/\/doi.org\/10.3389\/fnins.2023.1188847","journal-title":"Front Neurosci"},{"key":"1843_CR81","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/S0924-9338(97)83296-8","volume":"12","author":"Y Lecrubier","year":"1997","unstructured":"Lecrubier Y, Sheehan D, Weiller E, Amorim P, Bonora I, Sheehan KH, Janavs J, Dunbar G (1997) The Mini International Neuropsychiatric interview (MINI). A short diagnostic structured interview: reliability and validity according to the CIDI. Eur Psychiatry 12:224\u2013231. https:\/\/doi.org\/10.1016\/S0924-9338(97)83296-8","journal-title":"Eur Psychiatry"},{"key":"1843_CR82","unstructured":"Ackenheil M, Stotz-Ingenlath G, Dietz-Bauer R, Vossen A (1999) MINI mini international neuropsychiatric interview, German version 5.0. 0 DSM IV. Munich Psychiatr Univ Clin"},{"key":"1843_CR83","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.pbb.2005.11.013","volume":"82","author":"M Verleye","year":"2005","unstructured":"Verleye M, Akwa Y, Liere P, Ladurelle N, Pianos A, Eychenne B, Schumacher M, Gillardin J-M (2005) The anxiolytic etifoxine activates the peripheral benzodiazepine receptor and increases the neurosteroid levels in rat brain. Pharmacol Biochem Behav 82:712\u2013720. https:\/\/doi.org\/10.1016\/j.pbb.2005.11.013","journal-title":"Pharmacol Biochem Behav"},{"key":"1843_CR84","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.psyneuen.2017.05.022","volume":"83","author":"P Liere","year":"2017","unstructured":"Liere P, Pianos A, Oudinet J-P, Schumacher M, Akwa Y (2017) Differential effects of the 18-kDa translocator protein (TSPO) ligand etifoxine on steroidogenesis in rat brain, plasma and steroidogenic glands: pharmacodynamic studies. Psychoneuroendocrinology 83:122\u2013134. https:\/\/doi.org\/10.1016\/j.psyneuen.2017.05.022","journal-title":"Psychoneuroendocrinology"},{"key":"1843_CR85","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.steroids.2007.06.006","volume":"72","author":"L Kancheva","year":"2007","unstructured":"Kancheva L, Hill M, V\u010del\u00e1kov\u00e1 H, Vrb\u00edkov\u00e1 J, Pelik\u00e1nov\u00e1 T, St\u00e1rka L (2007) The identification and simultaneous quantification of neuroactive androstane steroids and their polar conjugates in the serum of adult men, using gas chromatography\u2013mass spectrometry. Steroids 72:792\u2013801. https:\/\/doi.org\/10.1016\/j.steroids.2007.06.006","journal-title":"Steroids"},{"key":"1843_CR86","first-page":"1","volume":"52","author":"E Baulieu","year":"1997","unstructured":"Baulieu E (1997) Neurosteroids: of the nervous system, by the nervous system, for the nervous system. Recent Prog Horm Res 52:1\u201332 PMID: 9238846","journal-title":"Recent Prog Horm Res"},{"key":"1843_CR87","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1196\/annals.1286.007","volume":"1007","author":"B Stoffel-Wagner","year":"2003","unstructured":"Stoffel-Wagner B (2003) Neurosteroid biosynthesis in the human brain and its clinical implications. Ann N Y Acad Sci 1007:64\u201378. https:\/\/doi.org\/10.1196\/annals.1286.007","journal-title":"Ann N Y Acad Sci"},{"key":"1843_CR88","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.neuint.2007.06.004","volume":"52","author":"D Caruso","year":"2008","unstructured":"Caruso D, Scurati S, Maschi O, De Angelis L, Roglio I, Giatti S, Garcia-Segura LM, Melcangi RC (2008) Evaluation of neuroactive steroid levels by liquid chromatography\u2013tandem mass spectrometry in central and peripheral nervous system: Effect of diabetes. Neurochem Int 52:560\u2013568. https:\/\/doi.org\/10.1016\/j.neuint.2007.06.004","journal-title":"Neurochem Int"},{"key":"1843_CR89","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1016\/j.psyneuen.2013.04.016","volume":"38","author":"D Caruso","year":"2013","unstructured":"Caruso D, Pesaresi M, Abbiati F, Calabrese D, Giatti S, Garcia-Segura LM, Melcangi RC (2013) Comparison of plasma and cerebrospinal fluid levels of neuroactive steroids with their brain, spinal cord and peripheral nerve levels in male and female rats. Psychoneuroendocrinology 38:2278\u20132290. https:\/\/doi.org\/10.1016\/j.psyneuen.2013.04.016","journal-title":"Psychoneuroendocrinology"},{"key":"1843_CR90","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.neuroscience.2011.05.054","volume":"191","author":"R Kancheva","year":"2011","unstructured":"Kancheva R, Hill M, Nov\u00e1k Z, Chrastina J, Kancheva L, St\u00e1rka L (2011) Neuroactive steroids in periphery and cerebrospinal fluid. Neuroscience 191:22\u201327. https:\/\/doi.org\/10.1016\/j.neuroscience.2011.05.054","journal-title":"Neuroscience"},{"key":"1843_CR91","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1186\/s13063-024-08120-x","volume":"25","author":"L-M Brunner","year":"2024","unstructured":"Brunner L-M, Riebel M, Wein S, Koller M, Zeman F, Huppertz G, Emmer T, Eberhardt Y, Schwarzbach J, Rupprecht R, Nothdurfter C (2024) The translocator protein 18\u00a0kDa ligand etifoxine in the treatment of depressive disorders\u2014a double-blind, randomized, placebo-controlled proof-of-concept study. Trials 25:274. https:\/\/doi.org\/10.1186\/s13063-024-08120-x","journal-title":"Trials"},{"key":"1843_CR92","doi-asserted-by":"publisher","first-page":"173321","DOI":"10.1016\/j.pbb.2021.173321","volume":"213","author":"JM Witkin","year":"2022","unstructured":"Witkin JM, Lippa A, Smith JL, Jin X, Ping X, Biggerstaff A (2022) The imidazodiazepine, KRM-II-81: an example of a newly emerging generations of GABAkines for neurological and psychiatric disorders. Phamacol Biochem Behav 213:173321. https:\/\/doi.org\/10.1016\/j.pbb.2021.173321","journal-title":"Phamacol Biochem Behav"}],"container-title":["European Archives of Psychiatry and Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-024-01843-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00406-024-01843-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-024-01843-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T12:15:53Z","timestamp":1759752953000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00406-024-01843-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,8]]},"references-count":92,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["1843"],"URL":"https:\/\/doi.org\/10.1007\/s00406-024-01843-7","relation":{},"ISSN":["0940-1334","1433-8491"],"issn-type":[{"value":"0940-1334","type":"print"},{"value":"1433-8491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,8]]},"assertion":[{"value":"29 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All clinical studies have been approved by the local ethics committee and have been performed in accordanve with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}},{"value":"The other authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"RR has received consultancy honoraria from SAGE\/Biogen and GABA Therapeutics.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}